Plans announced by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) to develop and publish a guideline on bioequivalence for modified-release products have been commended by the International Generic and Biosimilar Medicines Association (IGBA).
Generics Industry Welcomes Fresh ICH Harmonization Initiative
IGBA Lauds Plans For Guideline On Bioequivalence For Modified-Release Products
The International Council for Harmonisation has unveiled plans to develop and publish several new guidance documents, including one on bioequivalence for modified-release products, which has been welcomed by global off-patent industry body the IGBA.
More from International
More from Geography
• By
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
• By
The EU Clinical Trials Information System has achieved primary registry designation in the International Clinical Trials Registry Platform in a move that is expected to reduce regulatory burden for companies and help them lower compliance costs by aligning with publication requirements in medical journals.
• By
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.